Our live Investing Matters Podcast Special which took place at the Master Investor Show discussing 'How undervalued is the UK stock market?', has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Hello Digittt. Just to reassure you, I do not script my interviews. The only thing that there is a collaboration on is the time interviews will take place.
Agree...last years mania would have propelled it, but for the moment, until we get concrete news on it I don't think wil will do too much to SP. That being said...if announcements come out that are positive and it's a generic / repeatable, quick way of generating a vaccine for any flavour of virus, we would be in the pound seats...well at least the ten of pence seats. :-)
Added a few more @3.77p
I feel covid isn't going to have that much impact on SP now, unless the RNS is stunning and related to something which will help address variants. So many ongoing issues with variants at moment...
Also, as tuan has previously stated, Vlad mentioned the IP at this point is not worth much, that happens after clinical trials.
Vlad did say negotiations were ongoing and it looks like Global co will be assisting. He also said the issue was not with the product. However, he alluded to the fact signigicant finance was not ever going to be a part of the deal because Hemo would have lost complete control of the product. We do need finance to get to trials, so it is really up to how Mint behaves now and it seems how Mint behaves is out of Hemo's hands.
To be clear, on CBR - I don't think he said much new, but it does feel like we should hear something in the near term and I think that may have been enough last year to bring in the masses again.
The interviewer came across more scripted than Vlad, but the whole thing was clearly scripted, which was expected. All talk of everything but the bad news on CDX until nearing the end...as you'd expect. Although there is definitely more at play here than they just said "No", so that's helpful. I think it's done what was needed in terms of holding patterns. Unless Mint muck around, suspect SP will hold or bounce a little up for the next few weeks. If we do progress on CDX I expect to hear specific spend requirements for each stage and how they will be funded well in advance of the actual commitment taking place.
Wonder if we're still close enough to COVID sensitivity that the market will jump on the next potential CBR/COVID solution...ie given current negative headlines bouncing around on current vaccines etc. If he had made those statements last year in the summer and then hinted news was to come relatively shortly, we would have been trading a long way past our 15p peak. Suspect the COVID sensitivity though has dumbed down, so don't expect much yet from that. Happy to be wrong though!
Question is when will Mint convert...they have 9 million out of 12 million to go...
Sorry for double post. Lse playing up.
Think you should sell up pumpky. Clearly this investment isn't for you
Refreshingly honest interview. Key issues addressed clearly head on. How the communication continues. Unfortunately, looks like Mint is here to stay and Hemo currently have zero other options for financing to get to clinical trials. So much more short and medium term pain but hopefully a better outlook long term over next 5-10 years. Mint supposedly here for 8 years.
It's all about saving my portfo....I mean lives.
Refreshingly honest. Vlad came across well. Looks like we are stuck with Mint and no other financing options at the moment. So more short to medium term pain to pay for trials. Hopefully, longer term, this still has legs. I hope the communication continues. I really like the fact Vlad addressed the key points head on and clearly.
How many collaborations with Major companies before Hemo deliver?
Cdx product is still good to go clinical trials, I myself thought the product maybe not good enough but Vlad has confirmed product is perfect and deal is coming very soon. Hold on tight people and enjoy the ride
Collaboration with a giant company still ongoing and hopefully confirmed in the next Rns. I'm holding for sure and topping up big time
The usual suspects, always so negative!!! I'm losing the will sometimes, barely look at the board anymore.
My loss is only on paper right now, I encourage everyone to listen to the podcast and actually focus on the positives from it because there are many.
Good positive interview stating that everything's still on track and the market clearly overreacted to the last news. Should see some sort of recovery in SP hopefully.
Inflection point 2022.
Another PR disaster.
It was all about the deal. It was all about Mint.
Now it’s all about HEMO taking CDX further. Now Mint wrong decision.
The words ‘we were offered money from multiple sources’, actually appears incorrect.
Vlad could dilute the shares by another 50% and he would still be sitting pretty;unlike us:26 million already added:thats nearly 10%
Sorry BurtonD, I didn't refresh the page before I posted a link also!
HEMO podcast interview. (Link at bottom of page)
“…When we get into clinical trials we achieve an inflexion point for Hemogenyx and the price of our shares will follow…”
What is not under any doubt is that Hemogenyx Pharmaceuticals is developing breakthrough therapies for the treatment of blood diseases, and the company is confident an IND will be opened on its HEMO-CAR-T treatment of Acute Myeloid Leukemia by the end of this year.
‘IND’ is an acronym for Investigational New Drug which is a drug that is ready for clinical trials on humans. Another acronym applicable to the #HEMO story is ‘IGC’ or ‘it’s getting closer.’
Rewind 12 months when the stock surged 260% after the company announced it was using its advanced humanised mice to develop potential treatments for COVID-19. At the time the company said: “Although Hemogenyx has not traditionally been focused on fighting infectious diseases, we have always been focused on saving lives. In light of the current COVID-19 pandemic, we are determined to use our proprietary technology, expertise and resources to save lives and alleviate suffering.”
It’s proof that Hemogenyx is not a ‘one trick pony, but the word ‘suffering’ is poignant because as a major shareholder, co-founder and Chief Executive Dr Vladislav Sandler, experiences the pain of share price movements when they are not in the ascendancy. And the share price has been responding to events that are not related to the strides being made towards company-making inflexion points.
That of funder Mint Capital’s enthusiasm for convertible loan note conversions in respect of approximately £950,000 not once, but three times this year, and just months after #HEMO agreed a £60 million financing facility with the investment management company.
The sum was needed to progress the multi-stranded pipeline that has engaged the likes of Eli Lilly, global pharmaceutical company GlobalCo, the University of Pennsylvania. The funds were intended to give #HEMO greater choice in determining what strategic partnerships to pursue and on what terms.
The irony is that it’s the relationship with Mint Capital, and its perceived impatience, which is stealing the headlines and suppressing the investment value enhancing narrative as outlined by Sandler in this podcast with Sarah Lowther.
https://total-market-solutions.com/2021/04/hemogenyx-pharmaceuticals/